Format

Send to

Choose Destination
J Allergy Clin Immunol. 2016 Apr;137(4):1117-1127.e10. doi: 10.1016/j.jaci.2015.12.1316. Epub 2016 Mar 9.

Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy.

Author information

1
Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark. Electronic address: JonesStacieM@uams.edu.
2
Department of Pediatrics, University of North Carolina, Chapel Hill, NC.
3
Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Md.
4
Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.
5
Department of Pediatrics, National Jewish Health, Denver, Colo.
6
Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY.
7
EMMES Corporation, Rockville, Md.
8
National Institutes of Health (National Institute of Allergy and Infectious Diseases), Bethesda, Md.

Abstract

BACKGROUND:

We previously reported the results of a randomized placebo-controlled study of egg oral immunotherapy (eOIT) in which 27.5% of subjects achieved sustained unresponsiveness (SU) after 2 years. Here we report the results of treatment through 4 years and long-term follow-up.

OBJECTIVE:

We sought to evaluate the efficacy and safety of eOIT in participants treated up to 4 years.

METHODS:

Children with egg allergy (5-18 years old) received eOIT (n = 40) for up to 4 years or placebo (n = 15) for 1 year or less. The key outcome was the percentage of subjects achieving SU by year 4. Safety and immunologic assessments were performed, and long-term follow-up questionnaires (LFQs) were administered after study conclusion (LFQ-1) and 1 year later (LFQ-2).

RESULTS:

Of 40 eOIT-treated subjects, 20 (50.0%) of 40 demonstrated SU by year 4. For those subjects still dosing during years 3 and 4, mild symptoms were present in 12 (54.5%) of 22 subjects. At the time of the LFQ, more subjects receiving eOIT (LFQ-1, 23/34 [68%]; LFQ-2, 21/33 [64%]) were consuming unbaked and baked egg versus placebo (LFQ-1, 2/11 [18%], P = .006; LFQ-2, 3/12 [25%], P = .04). Of subjects achieving SU, 18 (90%) of 20 completed the LFQ, with 18 (100%) of 18 reporting consumption of all forms of egg. When compared with subjects not achieving SU, subjects achieving SU had higher IgG4 values (P = .001) and lower egg skin prick test scores (P = .0002) over time and a lower median baseline ratio of egg-specific IgE to total IgE (1.1% vs 2.7%, P = .04).

CONCLUSIONS:

SU after eOIT is enhanced with longer duration of therapy and increases the likelihood of tolerating unbaked egg in the diet.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00461097.

KEYWORDS:

Egg allergy; IgE; desensitization; follow-up; food allergy; immune tolerance; oral immunotherapy; sustained unresponsiveness

PMID:
26924470
PMCID:
PMC4826859
DOI:
10.1016/j.jaci.2015.12.1316
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center